NCT04266665View on ClinicalTrials.gov

Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome

PHASE4CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

March 12, 2020

Primary Completion Date

November 15, 2021

Study Completion Date

December 15, 2021

Conditions
Brain TumorMetabolic DisturbanceInflammatory ResponseOxygen Deficiency
Interventions
DRUG

Dexmedetomidine

Dexmedetomidine 2 μg/ml will be given as bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion

OTHER

Normal saline

Equivalent doses for a solution containing 2mcg/ml of the tested drug calculating for a bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion

Trial Locations (1)

54636

AHEPA University Hospital, Thessaloniki

All Listed Sponsors
lead

Georgia Tsaousi

OTHER

NCT04266665 - Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome | Biotech Hunter | Biotech Hunter